BR112023014287A2 - Análogos de rapamicina e usos dos mesmos - Google Patents
Análogos de rapamicina e usos dos mesmosInfo
- Publication number
- BR112023014287A2 BR112023014287A2 BR112023014287A BR112023014287A BR112023014287A2 BR 112023014287 A2 BR112023014287 A2 BR 112023014287A2 BR 112023014287 A BR112023014287 A BR 112023014287A BR 112023014287 A BR112023014287 A BR 112023014287A BR 112023014287 A2 BR112023014287 A2 BR 112023014287A2
- Authority
- BR
- Brazil
- Prior art keywords
- rapamicin
- analogs
- compositions
- compounds
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140523P | 2021-01-22 | 2021-01-22 | |
| US202163202524P | 2021-06-15 | 2021-06-15 | |
| PCT/US2022/070308 WO2022159976A1 (en) | 2021-01-22 | 2022-01-24 | Rapamycin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023014287A2 true BR112023014287A2 (pt) | 2023-11-21 |
Family
ID=82549982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023014287A BR112023014287A2 (pt) | 2021-01-22 | 2022-01-24 | Análogos de rapamicina e usos dos mesmos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220267352A1 (https=) |
| EP (1) | EP4281463A4 (https=) |
| JP (1) | JP2024503898A (https=) |
| KR (1) | KR20230136625A (https=) |
| AU (1) | AU2022209863A1 (https=) |
| BR (1) | BR112023014287A2 (https=) |
| CA (1) | CA3209086A1 (https=) |
| MX (1) | MX2023008634A (https=) |
| WO (1) | WO2022159976A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL285067B2 (en) | 2019-01-22 | 2025-02-01 | Aeovian Pharmaceuticals Inc | MTORC Modulators and Their Uses |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935110B (en) * | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| JP2010500286A (ja) * | 2006-07-25 | 2010-01-07 | アボット・ラボラトリーズ | 結晶形態のラパマイシン類似体 |
| EP2558092B1 (en) * | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| WO2012017449A1 (en) * | 2010-08-04 | 2012-02-09 | Meril Life Sciences Pvt. Ltd | Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties" |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| WO2019241789A1 (en) * | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| WO2020076738A2 (en) * | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| IL285067B2 (en) * | 2019-01-22 | 2025-02-01 | Aeovian Pharmaceuticals Inc | MTORC Modulators and Their Uses |
| AU2020397938A1 (en) * | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
-
2022
- 2022-01-24 US US17/648,750 patent/US20220267352A1/en not_active Abandoned
- 2022-01-24 MX MX2023008634A patent/MX2023008634A/es unknown
- 2022-01-24 CA CA3209086A patent/CA3209086A1/en active Pending
- 2022-01-24 JP JP2023544070A patent/JP2024503898A/ja active Pending
- 2022-01-24 AU AU2022209863A patent/AU2022209863A1/en not_active Abandoned
- 2022-01-24 BR BR112023014287A patent/BR112023014287A2/pt unknown
- 2022-01-24 WO PCT/US2022/070308 patent/WO2022159976A1/en not_active Ceased
- 2022-01-24 KR KR1020237027812A patent/KR20230136625A/ko active Pending
- 2022-01-24 EP EP22743426.3A patent/EP4281463A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4281463A4 (en) | 2025-07-23 |
| AU2022209863A1 (en) | 2023-09-07 |
| EP4281463A1 (en) | 2023-11-29 |
| MX2023008634A (es) | 2023-10-10 |
| CA3209086A1 (en) | 2022-07-28 |
| JP2024503898A (ja) | 2024-01-29 |
| WO2022159976A1 (en) | 2022-07-28 |
| KR20230136625A (ko) | 2023-09-26 |
| US20220267352A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018678A2 (pt) | Degradadores de mdm2 e usos dos mesmos | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| BR112023023223A2 (pt) | Degradadores de cdk2 e usos dos mesmos | |
| BR112023014287A2 (pt) | Análogos de rapamicina e usos dos mesmos | |
| BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
| CO2024011512A2 (es) | Degradadores de irak y usos de los mismos referencia a solicitudes relacionadas | |
| CL2022000603A1 (es) | Inhibidores prmt5 cooperativos de mta | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| MX2022006700A (es) | Compuestos poliheterociclicos como inhibidores de mettl3. | |
| CL2022000556A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
| CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
| BR112022010754A2 (pt) | Análogos de rapamicina e usos dos mesmos | |
| MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
| CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
| BR112017009601A2 (pt) | derivados de aminoácidos e seus usos | |
| MX2021006977A (es) | Anellosomas y metodos de uso. | |
| BR112022003704A2 (pt) | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl | |
| MX2021011376A (es) | Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos. | |
| CO2022002336A2 (es) | Compuestos heterocíclicos | |
| EA201791896A1 (ru) | Дезацетокситубулизин н и его аналоги | |
| MX383647B (es) | Análogos deuterados de etifoxina, sus derivados y usos de estos. | |
| BR112022003982A2 (pt) | Compostos heterocíclicos | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 |